Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.8K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Bone Formation by Endochondral Ossification01:24

Bone Formation by Endochondral Ossification

7.3K
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
7.3K
Growth of Cartilage and Bone Tissue01:27

Growth of Cartilage and Bone Tissue

3.8K
Chondrocytes form a temporary cartilaginous model by dividing and secreting a thick gel-like extracellular matrix. Once the chondrocytes undergo programmed cell death, osteoblasts enter the site of the cartilaginous model. The process of replacing the temporary cartilaginous model with bone in an ordered manner is called endochondral ossification. In endochondral ossification, not all of the cartilage is replaced by bone tissue. Some cartilage that performs a protective and supportive function...
3.8K
Cancer Therapies02:49

Cancer Therapies

9.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Tumor Progression02:07

Tumor Progression

6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

JCO precision oncology·2026
Same author

Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Diffusion-weighted imaging of bone and soft tissue tumors: a systematic review.

Acta radiologica (Stockholm, Sweden : 1987)·2026
Same author

Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Augmenting Osteosynthesis in Rotationplasty for Proximal Tibial Tumors: A Report of 2 Cases.

JBJS case connector·2025
Same journal

Surgical Fixation Versus Cast Immobilization for Adults With Bicortical Scaphoid Fractures: A Target Trial Emulation of the SWIFFT Trial.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same journal

Dementia as a Marker of Poor Outcome After Hip Hemiarthroplasty.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same journal

Fix or Replace: Evidence for Treatment Options in the Management of Femoral Neck Fractures.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same journal

Epidemiology, Treatment Patterns, and Comorbidities of Trigger Finger: A Contemporary Population-Based Analysis.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same journal

Posterior Approaches to Pilon Fractures: Considerations, Indications, and Outcomes.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same journal

Effect of Season on Patient-reported Outcomes and Discharge Disposition in Total Hip and Knee Arthroplasty.

The Journal of the American Academy of Orthopaedic Surgeons·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.9K

Chondrosarcoma.

Robert C Weinschenk1, Wei-Lien Wang, Valerae O Lewis

  • 1From the Department of Orthopaedic Oncology (Weinschenk, Lewis), and the Department of Pathology (Wang), The University of Texas MD Anderson Cancer Center, Houston, TX.

The Journal of the American Academy of Orthopaedic Surgeons
|February 17, 2021
PubMed
Summary
This summary is machine-generated.

Chondrosarcoma, a common bone tumor, varies significantly by grade. High-grade tumors have poor prognoses, while low-grade lesions are treatable, highlighting the importance of accurate grading for conventional chondrosarcoma management.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.4K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.4K

Related Experiment Videos

Last Updated: Nov 17, 2025

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.9K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.4K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.4K

Area of Science:

  • Orthopedic Oncology
  • Skeletal Pathology

Background:

  • Chondrosarcoma is the second most common primary bone tumor, with over 90% being the conventional subtype.
  • It can arise de novo or secondary to benign lesions like enchondromas or osteochondromas.
  • Pain is a common symptom, and tumor grade is a critical prognostic factor.

Purpose of the Study:

  • To summarize the clinical characteristics, prognostic factors, and treatment strategies for conventional chondrosarcoma.
  • To differentiate the outcomes and management approaches based on tumor grade.

Main Methods:

  • Review of existing literature on conventional chondrosarcoma.
  • Analysis of prognostic indicators, particularly tumor grade.
  • Evaluation of standard and emerging treatment modalities.

Main Results:

  • Grade I chondrosarcoma (atypical cartilaginous tumors) rarely metastasizes or recurs, with >80% 10-year survival.
  • Grade III chondrosarcoma has a poor prognosis, with >50% lung metastasis and <30% 10-year survival.
  • Conventional chondrosarcoma is resistant to chemotherapy and standard radiation.

Conclusions:

  • Complete surgical resection with wide margins is the standard for high-grade conventional chondrosarcoma.
  • Low-grade lesions may be treated with curettage, potentially with adjuvant local therapy.
  • Adjuvant therapies like chemotherapy or radiation show benefit in specific subtypes (dedifferentiated, mesenchymal chondrosarcoma), and advanced radiation techniques may aid treatment in complex anatomical sites.